GlassScriptPhysician profile
Ziad A Khatib
NPI 1902915820
$2,326.91
in general payments reported to CMS, 2019-2025
31 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $15.22 · 2021: $59.06 · 2022: $18.71 · 2023: $389 · 2024: $781 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.58 |
| Education | $146.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $397.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $353.58 | 2019-2024 | |
| Novo Nordisk INC | $167.36 | 2023-2025 | Novoeight, Rebinyn, Novoseven |
| Amgen INC. | $161.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.38 | 2019-2025 | |
| Day One Biopharmaceuticals | $134.22 | 2024-2025 | Ojemda |
| Genentech USA, INC. | $108.73 | 2019-2025 | Hemlibra |
| Pfizer INC. | $90.14 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $86.51 | 2023 | Koselugo |
| Springworks Therapeutics, INC. | $80.37 | 2025 | Gomekli |
| Takeda Pharmaceuticals U.S.A., INC. | $61.93 | 2023-2025 | Vpriv |
| Bard Peripheral Vascular, INC. | $59.06 | 2021 | |
| Astellas Pharma US INC | $56.73 | 2024-2025 | Cresemba |
| Genetix Biotherapeutics INC | $51.56 | 2024 | |
| Genzyme Corporation | $43.97 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $42.79 | 2024-2025 | Iwilfin |
| Agios Pharmaceuticals, INC. | $34.39 | 2023-2024 | Pyrukynd |
| Hema Biologics, LLC | $33.48 | 2024 | Sevenfact |
| Octapharma USA, INC. | $30.71 | 2019 | |
| Servier Pharmaceuticals LLC | $24.98 | 2024 | |
| Jazz Pharmaceuticals INC. | $24.58 | 2025 | |
| Rare Disease Therapeutics, INC. | $21.70 | 2024 | Purixan |
| Pharming Healthcare, INC. | $20.12 | 2024 | Ruconest |
| Emmaus Medical, INC. | $19.06 | 2024 | Endari |
| Csl Behring | $16.59 | 2024 | Hemgenix |
| Recordati_rare_diseases_inc. | $16.45 | 2024 | Panhematin |
| Btg International INC. | $15.57 | 2024 | |
| Biomarin Pharmaceutical INC. | $14.98 | 2023 | Roctavian |
| Allergan, INC. | $11.43 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Khatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.